Literature DB >> 7018166

Stimulation of labor in cases of premature rupture of the membranes at or near term. A consecutive randomized study of prostaglandin E2-tablets and intravenous oxytocin.

A P Lange, N J Secher, F H Nielsen, G T Pedersen.   

Abstract

Prostaglandin E2-tablets were compared to intravenous oxytocin for the stimulation of labor in 201 patients at or near term, with premature spontaneous rupture of the membranes without labor activity for 6 hours after the escape of fluid. The patients were randomly allocated; 99 were treated with PGE2-tablets (0.5-1.5 mg/hr) and 102 with intravenous oxytocin (7.5-45 mIU/min). The treatment was ineffective in the PGE2 group in 3 cases; these were treated successfully with intravenous oxytocin. In the oxytocin group, 3 patients were delivered by cesarean section for reasons not associated with the drug. A significant difference was found in the stimulation-delivery time, in favor of intravenous oxytocin. Although PGE2 tablets are a safe and convenient alternative to intravenous oxytocin, the investigation showed that intravenous oxytocin is preferable in cases of premature rupture of the membranes with more than 6 hours without labor activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7018166

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  3 in total

Review 1.  Moderately preterm, late preterm and early term infants: research needs.

Authors:  Tonse N K Raju
Journal:  Clin Perinatol       Date:  2013-09-20       Impact factor: 3.430

2.  Clinical trial comparing artificial rupture of membranes plus oral PGE2 tablets versus artificial rupture of membranes plus intravenous oxytocin for induction of labour in primigravid patients at term.

Authors:  S A Nassief; P McFaul; A Rane
Journal:  Ulster Med J       Date:  1996-11

3.  Labor induction in term nulliparous women with premature rupture of membranes: oxytocin versus dinoprostone.

Authors:  Nur Gozde Kulhan; Mehmet Kulhan
Journal:  Arch Med Sci       Date:  2018-06-01       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.